Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Melichar · SciRah

Researcher profile · Semantic Scholar

B. Melichar

Share profile

B. Melichar — researcher profile on SciRah

h-index: 63
Works: 555
Citations: 27K

Most-cited papers

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
R. Motzer, B. Alekseev, S. Rha, C. Porta +34 more
2021New England Journal of Medicine1,326 citations Open access
Semantic Scholar
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
F. Meric-Bernstam, V. Makker, A. Oaknin, Do-Youn Oh +14 more
2023Journal of Clinical Oncology794 citations Open access
Semantic Scholar
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
T. Choueiri, P. Tomczak, S. Park, B. Venugopal +29 more
2021New England Journal of Medicine608 citations Open access
Semantic Scholar
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
T. Powles, E. Plimack, D. Soulières, T. Waddell +16 more
2020The Lancet Oncology601 citations
Semantic Scholar
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
D. Miles, J. Gligorov, F. André, D. Cameron +155 more
2021Annals of Oncology597 citations Open access
Semantic Scholar
FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma.
U. Şahin, O. Türeci, G. Manikhas, F. Lordick +14 more
2021Annals of Oncology365 citations Open access
Semantic Scholar
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
R. Motzer, B. Escudier, D. McDermott, Osvaldo Arén Frontera +25 more
2020Journal for ImmunoTherapy of Cancer190 citations Open access
Semantic Scholar
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
E. Plimack, T. Powles, V. Stus, R. Gafanov +17 more
2023European Urology146 citations
Semantic Scholar
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
T. Choueiri, M. Eto, Robert J. Motzer, U. de Giorgi +24 more
2023The Lancet Oncology131 citations Open access
Semantic Scholar
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.
B. Rini, E. Plimack, V. Stus, T. Waddell +16 more
2021Journal of Clinical Oncology85 citations
Semantic Scholar
Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer
M. Svaton, M. Zemanova, P. Zemanová, J. Kultan +13 more
2020Anticancer Research84 citations Open access
Semantic Scholar
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
F. Meric-Bernstam, V. Makker, A. Oaknin, D. Oh +13 more
2023Journal of Clinical Oncology74 citations
Semantic Scholar
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.
B. Rini, E. Plimack, V. Stus, R. Gafanov +16 more
2023Journal of Clinical Oncology65 citations
Semantic Scholar
Non-invasive determination of uric acid in human saliva in the diagnosis of serious disorders
Andrea Vernerová, L. Kujovská-Krčmová, B. Melichar, F. Švec
2020Clinical Chemistry and Laboratory Medicine63 citations Open access
Semantic Scholar
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial
R. Motzer, P. Russo, N. Haas, C. Doehn +20 more
2021European Urology61 citations Open access
Semantic Scholar
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.
E. Plimack, B. Rini, V. Stus, R. Gafanov +16 more
2020Journal of Clinical Oncology54 citations
Semantic Scholar
Lipidomic characterization of exosomes isolated from human plasma using various mass spectrometry techniques.
Ondřej Peterka, Robert Jirásko, M. Chocholousková, L. Kuchař +6 more
2020Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids52 citations
Semantic Scholar
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
L. Rob, D. Cibula, P. Knapp, P. Mallmann +16 more
2022Journal for ImmunoTherapy of Cancer50 citations Open access
Semantic Scholar
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
K. Fizazi, G. Kramer, J. Eymard, C. Sternberg +19 more
2020The Lancet Oncology50 citations Open access
Semantic Scholar
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
D. Cibula, L. Rob, P. Mallmann, P. Knapp +22 more
2021Gynecologic Oncology43 citations Open access
Semantic Scholar
Plasma lipidomic profiles of kidney, breast and prostate cancer patients differ from healthy controls
Denise Wolrab, Robert Jirásko, Ondřej Peterka, Jakub Idkowiak +8 more
2021Scientific Reports38 citations Open access
Semantic Scholar
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study
Viktor Grünwald, T. Powles, E. Kopyltsov, V. Kozlov +16 more
2023European Urology Oncology37 citations Open access
Semantic Scholar
Radiation-associated angiosarcoma of the breast: An international multicenter analysis.
J. Mergancová, Anna Lierova, O. Coufal, J. Žatecký +27 more
2022Surgical oncology36 citations Open access
Semantic Scholar
Chromatographic method for the determination of inflammatory biomarkers and uric acid in human saliva.
Andrea Vernerová, L. Krčmová, Ondřej Heneberk, V. Radochová +4 more
2021Talanta: The International Journal of Pure and Applied Analytical Chemistry36 citations
Semantic Scholar
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial.
D. Adkins, Jin-Ching Lin, A. Sacco, J. Ley +14 more
2021Oral Oncology35 citations Open access
Semantic Scholar
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
J. Bedke, B. Rini, E. Plimack, V. Stus +17 more
2022European Urology33 citations
Semantic Scholar
Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
R. Motzer, C. Porta, M. Eto, T. Powles +16 more
2023Journal of Clinical Oncology31 citations
Semantic Scholar
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.
B. Rini, M. Atkins, E. Plimack, D. Soulières +15 more
2021European Urology Oncology29 citations
Semantic Scholar
Determination of one year stability of lipid plasma profile and comparison of blood collection tubes using UHPSFC/MS and HILIC-UHPLC/MS.
Denise Wolrab, M. Chocholousková, Robert Jirásko, Ondřej Peterka +4 more
2020Analytica Chimica Acta29 citations
Semantic Scholar
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
M. Simonelli, E. Garralda, F. Eskens, M. Gil-Martin +28 more
2022ESMO Open26 citations Open access
Semantic Scholar
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
C. Sternberg, D. Castellano, J. de Bono, K. Fizazi +16 more
2021European Urology24 citations Open access
Semantic Scholar
Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer
M. Kolečková, J. Ehrmann, J. Bouchal, M. Janíková +10 more
2021Scientific Reports24 citations Open access
Semantic Scholar
Comprehensive characterization of complex glycosphingolipids in human pancreatic cancer tissues
Karel Hořejší, C. Jin, Z. Vaňková, Robert Jirásko +4 more
2023Journal of Biological Chemistry22 citations Open access
Semantic Scholar
Robust and high-throughput lipidomic quantitation of human blood samples using flow injection analysis with tandem mass spectrometry for clinical use
Jakub Idkowiak, Robert Jirásko, Denisa Kolářová, J. Bártl +9 more
2023Analytical and Bioanalytical Chemistry20 citations
Semantic Scholar
Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature
H. Študentová, Jindřiška Voláková, M. Spisarová, A. Zemánková +3 more
2022BMC Gastroenterology20 citations Open access
Semantic Scholar
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
R. de Wit, C. Wülfing, D. Castellano, G. Kramer +16 more
2021ESMO Open20 citations Open access
Semantic Scholar
Intra-laboratory comparison of four analytical platforms for lipidomic quantitation using hydrophilic interaction liquid chromatography or supercritical fluid chromatography coupled to quadrupole - time-of-flight mass spectrometry.
M. Chocholousková, Denise Wolrab, Robert Jirásko, H. Študentová +2 more
2021Talanta: The International Journal of Pure and Applied Analytical Chemistry19 citations
Semantic Scholar
Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms.
Viktor Grünwald, T. Powles, E. Kopyltsov, V. Kozlov +16 more
202118 citations
Semantic Scholar
Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
Alena Novakova-Jiresova, K. Kopeckova, L. Boublikova, R. Chloupková +10 more
2020Cancer Management and Research18 citations Open access
Semantic Scholar
Altered Plasma, Urine, and Tissue Profiles of Sulfatides and Sphingomyelins in Patients with Renal Cell Carcinoma
Robert Jirásko, Jakub Idkowiak, Denise Wolrab, A. Kvasnička +6 more
2022medRxiv16 citations Open access
Semantic Scholar
The Evolving Landscape of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma
H. Študentová, M. Spisarová, Andrea Kopová, A. Zemánková +2 more
2023Cancers15 citations Open access
Semantic Scholar
Rethinking internal quality control: the time is now
M. Plebani, P. Gillery, Ronda F. Graves, K. Lackner +4 more
2022Clinical Chemistry and Laboratory Medicine14 citations Open access
Semantic Scholar
Cost analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and the risk factors for their increased cost in a public insurance health care system - Single centre study.
D. Klos, J. Riško, Dominika Kriváčková, M. Loveček +5 more
2020European Journal of Surgical Oncology14 citations Open access
Semantic Scholar
Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
O. Fiala, J. Finek, A. Poprach, B. Melichar +7 more
2020Cancers14 citations Open access
Semantic Scholar
Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy—Data from the National Renis Registry
A. Poprach, M. Holánek, R. Chloupková, R. Lakomý +9 more
2020Cancers13 citations Open access
Semantic Scholar
Biomarkers in the management of lung cancer: changing the practice of thoracic oncology
B. Melichar
2022Clinical Chemistry and Laboratory Medicine12 citations
Semantic Scholar
The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature
H. Študentová, N. Rušarová, Andrea Ondrušková, A. Zemánková +3 more
2022Current Oncology12 citations Open access
Semantic Scholar
718P A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment
T. Powles, S. Oudard, Viktor Grünwald, E. Calvo +8 more
202011 citations Open access
Semantic Scholar
Neopterin and kynurenine in serum and urine as prognostic biomarkers in hospitalized patients with delta and omicron variant SARS-CoV-2 infection
L. Krčmová, Kateřina Matoušová, L. Javorská, P. Šmahel +6 more
2023Clinical Chemistry and Laboratory Medicine10 citations Open access
Semantic Scholar
Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib
T. Buchler, M. Kopecká, A. Zemánková, M. Wiesnerová +5 more
2020Targeted oncology10 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Powles×15
Invite
T. Powles — researcher profile on SciRah
H. Študentová×8
Invite
H. Študentová — researcher profile on SciRah
Viktor Grünwald×7
Invite
Viktor Grünwald — researcher profile on SciRah
J. Bedke×7
Invite
J. Bedke — researcher profile on SciRah

×7

Invite

D. Soulières — researcher profile on SciRah

I. Vynnychenko×7

Invite

I. Vynnychenko — researcher profile on SciRah

Invite

B. Rini — researcher profile on SciRah

Robert Jirásko×7

Invite

Robert Jirásko — researcher profile on SciRah

M. Holčapek×7

Invite

M. Holčapek — researcher profile on SciRah

Invite

B. Alekseev — researcher profile on SciRah

Invite

T. Choueiri — researcher profile on SciRah

Invite

V. Stus — researcher profile on SciRah